Triple Negative Breast Cancer Novel Immunotherapy Approach Developed

Triple Negative Breast Cancer Novel Immunotherapy Approach Developed
A novel immunotherapy approach, developed by ImMAGE Biotherapeutics to treat triple negative breast cancer (TNBC), shows promising results in laboratory culture studies and is now being tested in animal models. The company hopes to take the potential treatment onto a Phase 1 clinical trial by the end of 2017, and into the market within the next seven to ten years. “After completing in vitro trials, I’m even more confident in our team’s ability to transform ground breaking research into a tangible patient therapy. All of our results were strong and conclusive -- some even better than we anticipated,” said Mahesh Narayanan, chief operating officer of ImMAGE Biotherapeutics, in a press release. “Right now we’re witnessing an immunotherapy revolution in cancer treatment, especially in the U.S., and we plan to play a big part for TNBC and other cancers as we begin our animal testing phase.” The immunotherapy approach developed by ImMAGE Biotherapeutics works by stimulating the body’s immune system to specifically target tumor cells. Here's a summary:  A piece of DNA that codes for a short chain of amino acids, also called antigenic peptides, is delivered into the body. The antigenic peptides are similar to a protein called MAGE A found on the surface of tumor cells. The antigenic peptides encoded by the injected DNA stimulate the production of specific cells of the immune system that can recognize the MAGE A protein found on the surface of tumor cells. This means that the tumor cells can be specifically sought and destroyed. The antigenic peptides also stimulate the production of tumor specific antibodies, which mark tumor cells for destruction. During in vitr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.